|
|
HIV Update 2002 (10) - OctoberPublished by: Datamonitor Published: Nov. 19, 2002 - 21 Pages Table of ContentsOverview Introduction Provides an account of all the key market events that took place during October 2002. Key events include new product launches, clinical trial data and conference findings. Scope Key events are analyzed in the HIV market during October Coverage includes emerging market headlines, R&D pipeline data, epidemiology and disease specific factors Reasons to Purchase Stay informed of all of the important market led events taking place in the HIV market Gain insight into the likely market impact of the events that took place in October 2002 in the HIV market Report Highlights Future of HIV therapy lies in simplication of drug regimens Effective capture of switching patient populations will determine future commercial returns Structured treatment interruptions will play an important role in future HIV treatment DRIVERS AND TRENDS Simplification of HIV therapy will start to play a more dominant role in the next two to three years. Strategies to reduce pill burden and dosage requirements will need to be driven by patient unmet needs. To compete effectively in the HIV sector, competitors should seek to reformulate existing products and develop novel products with once daily dosing profiles. The HIV market is driven to a large extent by drug switching, especially in patients entering latter stage therapy. This is due to the nature of the viral infection and the fast mutation rate of the virus. Datamonitor forecasts an increase in latter stage patients in the next two to three years. HIV drug manufacturers should continue to target this niche patient population to generate the greatest revenue. Structured treatment interruptions is a treatment strategy that will experience increased use in the near future. This strategy may be used for a number of different patient populations. If patient compliance increases due to a decrease in side effects with this treatment strategy, patients may be kept longer on these strategies. Thus, the long-term profitability of drugs used in these patients will increase. COMPANY HEADLINES A summary of the latest events from a company perspective GlaxoSmithKline Faces Amended Lawsuit Regarding Patent Rights RESEARCH AND DEVELOPMENT HEADLINES A summary of the key events from a pipeline drug perspective Clarithromycin Not Best Choice for MAC Prophylaxis in HIV Patients Treated with Zidovudine Once Daily Regimens Effective in Treatment Naïve Patients 2002: The Third Wave of HIV Vaccine Development Switching to Sustiva Beneficial in Children on Protease Inhibitors Filgrastim May Prevent Decrease in Viral Load Associated with PI Therapy Atazanavir Shows Good Safety and Efficacy in Treatment- Naive Patients DISEASE SPECIFIC HEADLINES An overview of the epidemiological, research and clinical perspective HIV Incidence in Intravenous Drug Users Decreases in the US Supervised Treatment Interruption of HIV Treatment May be Effective and Safe HAART May Not Contribute to Cardiovascular Risk in the Short Term Wild-type Virus Persists in Treatment-Experienced HIV-infected Children HIV Replication Can Be Blocked by RNA Interference Techniques Treatment for FIV Shows Efficacy in HIV Drug Resistance Common in Pediatric HIV-infected Individuals Call for AIDS Vaccine Intensifies HAART-Related Dyslipidemia Treated by Diet PI Use May Accelerate Coronary Atherosclerosis EMERGING MARKETS HEADLINES A summary of the key events from the emerging markets CIA Highlights HIV Explosion Risk HIV Individuals in Thailand May Receive Cheap AIDS Drug Africa AIDS Drugs Illegally Re-exported to EU No Resolution Over Supply of Cheap Drugs to WTO Nations AbstractThis brief provides an account of all the key market events that took place during October 2002. Key events include new product launches, clinical trial data and conference findings.Key events are analyzed in the HIV market during OctoberCoverage includes emerging market headlines, R&D pipeline data, epidemiology and disease specific factorsFuture of HIV therapy lies in simplication of drug regimensEffective capture of switching patient populations will determine future commercial returnsStructured treatment interruptions will play an important role in future HIV treatmentStay informed of all of the important market led events taking place in the HIV marketGain insight into the likely market impact of the events that took place in October 2002 in the HIV marketGet Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||